Literature DB >> 32594232

Predictors of mortality in patients with primary spinal cord glioblastoma.

Lei Cheng1, Qingyu Yao1, Longbing Ma1, Wanru Duan1, Jian Guan1, Can Zhang1, Kai Wang1, Zhenlei Liu1, Fengzeng Jian2, Hao Wu1, Zan Chen1, Xingwen Wang1, Zuowei Wang1.   

Abstract

PURPOSE: Primary spinal cord glioblastoma (GBM) is a rare and devastating disease. Little attention was ever paid to this rare disease. As a result, the standard treatment protocol and prognostic factors of primary spinal cord GBM were not well established. The aim of this study was to determine the predictors associated with survival in patients with primary spinal cord GBM.
METHODS: A total of 122 patients with primary spinal cord GBM from Surveillance, Epidemiology, and End Results database and our institution were included in this retrospective analysis. Information about age, sex, race, tumor invasion, extent of resection, radiation, chemotherapy and year of diagnosis was collected. Univariate and multivariate accelerated failure time (AFT) regression model was performed to identify prognostic factors.
RESULTS: Of the 122 patients, 102 (83.6%) expired at the time of data collection. Overall survival at 1 year, 2 years, 3 years and 5 years was 48.4%, 22.8%, 17.1% and 8.4%, respectively, and median survival time was 12 months. Only radiation was found to be associated with survival in the AFT regression model (time ratio 1.94, 95% CI 1.01-3.72, p < 0.05). Radiotherapy could improve survival slightly; patients who received RT survived approximately two times as long as patients who did not receive RT, but the advantage was short term.
CONCLUSION: The survival of primary spinal cord GBM is poor in the current treatment strategy. Radiotherapy was associated with better survival, but the advantage was short term.

Entities:  

Keywords:  Glioblastoma; Prognostic factors; Radiotherapy; Spinal cord; Survival

Mesh:

Year:  2020        PMID: 32594232     DOI: 10.1007/s00586-020-06515-3

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  3 in total

1.  Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with FGFR3 Mutation.

Authors:  Ruiqiong Liu; Wei Wei; Huaying Hou; Ping Cong; Yong Zhou; Xiaoming Yu
Journal:  Onco Targets Ther       Date:  2022-07-11       Impact factor: 4.345

2.  Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas.

Authors:  Huy Gia Vuong; Tam N M Ngo; Hieu Trong Le; Andrew Jea; Maya Hrachova; James Battiste; Rene McNall-Knapp; Ian F Dunn
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

3.  Atypical imaging features of the primary spinal cord glioblastoma: A case report.

Authors:  Xin-Yu Liang; Yao-Ping Chen; Qiao Li; Ze-Wang Zhou
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.